Abstract



1

2

3

4

5

6 7

8 9

10

11

12

13

14

15

16

## In vitro anticancer effects of 1,2,4-triazole-3-carboxamides \*

Diana Grigoreva <sup>1,\*</sup>, Lyubov Grebenkina <sup>2</sup>, Varvara Maksimova <sup>1</sup>, Ekaterina Mikhina <sup>2</sup>, Ekaterina Lesovaya <sup>1,3,4</sup>, Andrey Matveev <sup>2</sup>, Marianna Yakubovskaya <sup>1</sup> and Ekaterina Zhidkova <sup>1</sup>

- <sup>1</sup> N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 24 Kashirskoe Shosse, Moscow, 115478, Russia; lavarvar@gmail.com (V.M.); lesovenok@yandex.ru (E.L.); mgyakubovskaya@mail.ru (M.Y.); zhidkova\_em@mail.ru (E.Z.)
- <sup>2</sup> MIREA Russian Technological University, Lomonosov Institute of Fine Chemical Technologies; 78 Vernadsky Avenue, Moscow 119571, Russia; legrebenkina@mail.ru (L.G.); mik.hi@mail.ru (E.M.); 4motya@gmail.com (A.M.)
- <sup>3</sup> I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia; 9 Vysokovol'tnaya St., Ryazan, 390026, Russia
- <sup>4</sup> Peoples' Friendship University of Russia; 6 Miklukho-Maklaya St., Moscow 117198, Russia
- \* Correspondence: grigodidmit@gmail.com
- + Presented at the 9th International Electronic Conference on Medicinal Chemistry, available online: https://ecmc2023.sciforum.net/, 1–30 Nov 2023.

Abstract: Ovarian cancer (OVC) is a current health problem for women around the world. The high 17 mortality rate from OVC makes the development of new therapeutic drugs relevant. Ribavirin 18 (RBV, chemical name 1,2,4-triazole-3-carboxamide) is commonly used as an antiviral agent. In re-19 cent years, research has focused on repurposing RBV as an anticancer drug. However, RBV reveals 20 a number of side effects, so synthetic derivatives of 1,2,4-triazole-3-carboxamide (TCA) are being 21 actively developed and tested as putative anticancer drugs. The purpose of this study is to estimate 22 the anticancer effects of RBV, TCA and its derivatives (MGs) in vitro. Cytotoxic effect of the MGs on 23 ovarian cancer cells (OVAR3 and OVAR4) was assessed using the MTT assay. The proliferation rate 24 of OVC cells was assessed after 72 h of treatment RBV, TCA and MGs cell counting with trypan blue 25 exclusion. Distribution of cell cycle phases was evaluated using flow cytometry with PI stain-26 ing. RBV and MGs induced 40% cell death in OVC cells. MGs inhibited proliferation by 50-70% in 27 OVC cells. After 72h RBV and MGs induces S-phase stunting. Furthermore, we demonstrated an 28 increase in the number of cells in the subG1 phase (2.5%) after treatment with MG0 and MG1, as 29 well as in G2/M-phase (10%) after treatment with MG5. According to the results obtained, 1,2,4-30 triazole-3-carboxamides can inhibit proliferation and induce apoptosis in vitro. These results pro-31 vide the rationale for further studies of 1,2,4-triazole-3-carboxamides like anticancer drugs. 32

Keywords: ovarian cancer; ribavirin; 1,2,4-triazole-3-carboxamides; cell cycle

33 34

35

36

Supplementary Materials:

Author Contributions: Conceptualization, E.Z. and A.M.; methodology, V.M.; software, D.G.; vali-37dation, L.G., V.M. and E.M.; formal analysis, E.M.; investigation, D.G.; resources, M.Y. and A.M.;38data curation, E.Z.; writing—original draft preparation, D.G.; writing—review and editing, E.L.;39visualization, L.G.; supervision, E.L.; project administration, M.Y.; funding acquisition, E.Z. All au-40thors have read and agreed to the published version of the manuscript.41

**Funding:** This research was supported by the Russian science foundation grant №23-25-00382. 42

Institutional Review Board Statement: Not applicable.

43

Citation: Grigoreva, D.; Grebenkina, L.; Maksimova, V.; Mikhina, E.; Lesovaya, E.; Matveev, A.; Yakubovskaya, M.; Zhidkova, E. *In vitro* anticancer effects of 1,2,4-triazole-3-carboxamides. *Med. Sci. Forum* 2023, 2, x.

https://doi.org/10.3390/xxxxx

Academic Editor: Firstname Lastname

Published: date

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licens es/by/4.0/).

Informed Consent Statement: Not applicable.	1
<b>Data Availability Statement:</b> The data presented in this study are available on request from the corresponding author.	2 3
Acknowledgments: Conflicts of Interest: The authors declare no conflict of interest.	4 5
	6